Heart Failure with Preserved Ejection Fraction

  • Scott L. HummelEmail author


Of the millions of heart failure heart failure patients worldwide, approximately half present with preserved left ventricular ejection fraction (HFPEF). HFPEF has high rates of morbidity and mortality, yet therapy remains empirical due to incomplete understanding of disease pathophysiology. Systemic hypertension is the most prominent risk factor for HFPEF. Patients often have multiple other comorbid conditions, which may contribute to symptom burden and the HFPEF syndrome itself. The classic paradigm of ventricular diastolic dysfunction has expanded, and vascular dysfunction likely contributes to HFPEF in many patients. Pressure-volume loop analysis identifies three distinct hemodynamic phenotypes for HFPEF, a finding which may have significant implications for clinical trial enrollment and individual patient treatment.


Heart Failure Diastolic Vascular Stiffness Hypertension Elderly Endothelial dysfunction 


  1. 1.
    Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Tribouilloy C, Rusinaru D, Mahjoub H, Souliere V, Levy F, Peltier M, Slama M, Massy Z. Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study. Eur Heart J. 2008;29:339–47.PubMedCrossRefGoogle Scholar
  3. 3.
    Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, O’Connor CM, Sun JL, Yancy CW, Young JB. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF registry. J Am Coll Cardiol. 2007;50:768–77.PubMedCrossRefGoogle Scholar
  4. 4.
    Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC, ADHERE Scientific Advisory Committee and Investigators. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated HEart failure national REgistry (ADHERE) database. J Am Coll Cardiol. 2006;47:76–84.PubMedCrossRefGoogle Scholar
  5. 5.
    Abramov D, He K-L, Wang J, Burkhoff D, Maurer MS. The impact of extra cardiac comorbidities on pressure volume relations in heart failure and preserved ejection fraction. J Card Fail. 2011;17:547–55.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Mohammed SF, Borlaug BA, Roger VL, Mirzoyev SA, Rodeheffer RJ, Chirinos JA, Redfield MM. Comorbidity and ventricular and vascular structure and function in heart failure with preserved ejection fraction: a community-based study. Circ Heart Fail. 2012;5:710–9.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Campbell RT, Jhund PS, Castagno D, Hawkins NM, Petrie MC, McMurray JJV. What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE? J Am Coll Cardiol. 2012;60:2349–56.PubMedCrossRefGoogle Scholar
  8. 8.
    Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, Marino P, Smiseth OA, De Keulenaer G, Leite-Moreira AF, Borbely A, Edes I, Handoko ML, Heymans S, Pezzali N, Pieske B, Dickstein K, Fraser AG, Brutsaert DL. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007;28:2539–50.PubMedCrossRefGoogle Scholar
  9. 9.
    Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure – abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med. 2004;350:1953–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Chen CH, Fetics B, Nevo E, Rochitte CE, Chiou KR, Ding PA, Kawaguchi M, Kass DA. Noninvasive single-beat determination of left ventricular end-systolic elastance in humans. J Am Coll Cardiol. 2001;38:2028–34.PubMedCrossRefGoogle Scholar
  11. 11.
    Redfield MM, Jacobsen SJ Jr CBJ, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003;289:194–202 [see comment].PubMedCrossRefGoogle Scholar
  12. 12.
    Lam CSP, Lyass A, Kraigher-Krainer E, Massaro JM, Lee DS, Ho JE, Levy D, Redfield MM, Pieske BM, Benjamin EJ, Vasan RS. Cardiac dysfunction and noncardiac dysfunction as precursors of heart failure with reduced and preserved ejection fraction in the community/clinical perspective. Circulation. 2011;124:24–30.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Peterson GE, de Backer T, Contreras G, Wang X, Kendrick C, Greene T, Appel LJ, Randall OS, Lea J, Smogorzewski M, Vagaonescu T, Phillips RA. Relationship of left ventricular hypertrophy and diastolic function with cardiovascular and renal outcomes in African-Americans with hypertensive chronic kidney disease. Hypertension. 2013;62:518–25.PubMedCrossRefGoogle Scholar
  14. 14.
    Aurigemma GP, Gottdiener JS, Shemanski L, Gardin J, Kitzman D. Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: The Cardiovascular Health Study. J Am Coll Cardiol. 2001;37:1042–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Melenovsky V, Borlaug BA, Rosen B, Hay I, Ferruci L, Morell CH, Lakatta EG, Najjar SS, Kass DA. Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. J Am Coll Cardiol. 2007;49:198–207.PubMedCrossRefGoogle Scholar
  16. 16.
    Maurer MS, King DL, El-Khoury Rumbarger L, Packer M, Burkhoff D. Left heart failure with a normal ejection fraction: identification of different pathophysiologic mechanisms. J Card Fail. 2005;11:177–87.PubMedCrossRefGoogle Scholar
  17. 17.
    Lam CSP, Roger VL, Rodeheffer RJ, Bursi F, Borlaug BA, Ommen SR, Kass DA, Redfield MM. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation. 2007;115:1982–90.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Westermann D, Kasner M, Steendijk P, Spillmann F, Riad A, Weitmann K, Hoffmann W, Poller W, Pauschinger M, Schultheiss H-P, Tschope C. Role of left ventricular stiffness in heart failure with normal ejection fraction. Circulation. 2008;117:2051–60.PubMedCrossRefGoogle Scholar
  19. 19.
    Borlaug BA, Jaber WA, Ommen SR, Lam CSP, Redfield MM, Nishimura RA. Diastolic relaxation and compliance reserve during dynamic exercise in heart failure with preserved ejection fraction. Heart. 2011;97:964–9.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Donaldson C, Palmer BM, Zile M, Maughan DW, Ikonomidis JS, Granzier H, Meyer M, VanBuren P, LeWinter MM. Myosin cross-bridge dynamics in patients with hypertension and concentric left ventricular remodeling. Circ Heart Fail. 2012;5:803–11.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Gandhi SK, Powers JC, Nomeir A-M, Fowle K, Kitzman DW, Rankin KM, Little WC. The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med. 2001;344:17–22.PubMedCrossRefGoogle Scholar
  22. 22.
    Noumi B, Teruya S, Salomon S, Helmke S, Maurer MS. Blood volume measurements in patients with heart failure and a preserved ejection fraction: implications for diagnosing anemia. Congest Heart Fail. 2011;17:14–8.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Hundley WG, Kitzman DW, Morgan TM, Hamilton CA, Darty SN, Stewart KP, Herrington DM, Link KM, Little WC. Cardiac cycle-dependent changes in aortic area and distensibility are reduced in older patients with isolated diastolic heart failure and correlate with exercise intolerance. J Am Coll Cardiol. 2001;38:796–802.Google Scholar
  24. 24.
    Redfield MM, Jacobsen SJ, Borlaug BA, Rodeheffer RJ, Kass DA. Age- and gender-related ventricular-vascular stiffening: a community-based study. Circulation. 2005;112:2254–62.PubMedCrossRefGoogle Scholar
  25. 25.
    Kawaguchi M, Hay I, Fetics B, Kass DA. Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation. 2003;107:714–20.PubMedCrossRefGoogle Scholar
  26. 26.
    Borlaug BA, Lam CSP, Roger VL, Rodeheffer RJ, Redfield MM. Contractility and ventricular systolic stiffening in hypertensive heart disease: insights into the pathogenesis of heart failure with preserved ejection fraction. J Am Coll Cardiol. 2009;54:410–8.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Zhong L. Attenuation of stress-based ventricular contractility in patients with heart failure and normal ejection fraction. Ann Acad Med Singapore. 2011;40:179–85.PubMedGoogle Scholar
  28. 28.
    Kitzman DW, Herrington DM, Brubaker PH, Moore JB, Eggebeen J, Haykowsky MJ. Carotid arterial stiffness and its relationship to exercise intolerance in older patients with heart failure and preserved ejection fraction. Hypertension. 2013;61:112–9.PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Tartière-Kesri L, Tartière J-M, Logeart D, Beauvais F, Cohen SA. Increased proximal arterial stiffness and cardiac response with moderate exercise in patients with heart failure and preserved ejection fraction. J Am Coll Cardiol. 2012;59:455–61.PubMedCrossRefGoogle Scholar
  30. 30.
    Borlaug BA, Olson TP, Lam CSP, Flood KS, Lerman A, Johnson BD, Redfield MM. Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2010;56:845–54.PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Haykowsky MJ, Brubaker PH, John JM, Stewart KP, Morgan TM, Kitzman DW. Determinants of exercise intolerance in elderly heart failure patients with preserved ejection fraction. J Am Coll Cardiol. 2011;58:265–74.PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Hundley WG, Bayram E, Hamilton CA, Hamilton EA, Morgan TM, Darty SN, Stewart KP, Link KM, Herrington DM, Kitzman DW. Leg flow-mediated arterial dilation in elderly patients with heart failure and normal left ventricular ejection fraction. Am J Physiol Heart Circ Physiol. 2007;292:H1427–34.PubMedCrossRefGoogle Scholar
  33. 33.
    Haykowsky MJ, Herrington DM, Brubaker PH, Morgan TM, Hundley WG, Kitzman DW. Relationship of flow-mediated arterial dilation and exercise capacity in older patients with heart failure and preserved ejection fraction. J Gerontol A Biol Sci Med Sci. 2013;68:161–7.PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Houghton JL, Frank MJ, Carr AA, von Dohlen TW, Prisant LM. Relations among impaired coronary flow reserve, left ventricular hypertrophy and thallium perfusion defects in hypertensive patients without obstructive coronary artery disease. J Am Coll Cardiol. 1990;15:43–51.PubMedCrossRefGoogle Scholar
  35. 35.
    Westermann D, Lindner D, Kasner M, Zietsch C, Savvatis K, Escher F, von Schlippenbach J, Skurk C, Steendijk P, Riad A, Poller W, Schultheiss H-P, Tschöpe C. Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction/clinical perspective. Circ Heart Fail. 2011;4:44–52.PubMedCrossRefGoogle Scholar
  36. 36.
    McMurray JJV, Morton J, Ferrell W, Padmanabhan N, Balmain S. Differences in arterial compliance, microvascular function and venous capacitance between patients with heart failure and either preserved or reduced left ventricular systolic function. Eur J Heart Fail. 2007;9:865–71.PubMedCrossRefGoogle Scholar
  37. 37.
    Akiyama E, Sugiyama S, Matsuzawa Y, Konishi M, Suzuki H, Nozaki T, Ohba K, Matsubara J, Maeda H, Horibata Y, Sakamoto K, Sugamura K, Yamamuro M, Sumida H, Kaikita K, Iwashita S, Matsui K, Kimura K, Umemura S, Ogawa H. Incremental prognostic significance of peripheral endothelial dysfunction in patients with heart failure with normal left ventricular ejection fraction. J Am Coll Cardiol. 2012;60:1778–86.PubMedCrossRefGoogle Scholar
  38. 38.
    Maurer MS, Burkhoff D, Fried LP, Gottdiener J, King DL, Kitzman DW. Ventricular structure and function in hypertensive participants with heart failure and a normal ejection fraction: the Cardiovascular Health Study. J Am Coll Cardiol. 2007;49:972–81.PubMedCrossRefGoogle Scholar
  39. 39.
    Colombo PC, Banchs JE, Celaj S, Talreja A, Lachmann J, Malla S, DuBois NB, Ashton AW, Latif F, Jorde UP, Ware JA, LeJemtel TH. Endothelial cell activation in patients with decompensated heart failure. Circulation. 2005;111:58–62.PubMedCrossRefGoogle Scholar
  40. 40.
    Colombo P, Rastogi S, Onat D, Zac V, Gupta R, Jorde U, Sabbah H. Activation of endothelial cells in conduit veins of dogs with heart failure and veins of normal dogs after vascular stretch by acute volume loading. J Card Fail. 2009;15:457–63.PubMedCrossRefGoogle Scholar
  41. 41.
    Colombo PC, Onat D, Sabbah HN. Acute heart failure as “acute endothelitis” – interaction of fluid overload and endothelial dysfunction. Eur J Heart Fail. 2008;10:170–5.PubMedCrossRefGoogle Scholar
  42. 42.
    Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation. 2011;124:164–74.PubMedCrossRefGoogle Scholar
  43. 43.
    Borlaug BA, Melenovsky V, Russell SD, Kessler K, Pacak K, Becker LC, Kass DA. Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation. 2006;114:2138–47.PubMedCrossRefGoogle Scholar
  44. 44.
    Kosmala W, Holland DJ, Rojek A, Wright L, Przewlocka-Kosmala M, Marwick TH. Effect of If-channel inhibition on hemodynamics and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. J Am Coll Cardiol. 2013;62:1330–8.PubMedCrossRefGoogle Scholar
  45. 45.
    Obokata M, Negishi K, Kurosawa K, Arima H, Tateno R, Ui G, Tange S, Arai M, Kurabayashi M. Incremental diagnostic value of LA strain with leg lifts in heart failure with preserved ejection fraction. JACC Cardiovasc Imaging. 2013;6:749–58.PubMedCrossRefGoogle Scholar
  46. 46.
    McKie PM, Schirger JA, Costello-Boerrigter LC, Benike SL, Harstad LK, Bailey KR, Hodge DO, Redfield MM, Simari RD, Burnett Jr JC, Chen HH. Impaired natriuretic and renal endocrine response to acute volume expansion in pre-clinical systolic and diastolic dysfunction. J Am Coll Cardiol. 2011;58:2095–103.PubMedCrossRefGoogle Scholar
  47. 47.
    Maurer MS, Teruya S, Chakraborty B, Helmke S, Mancini D. Treating anemia in older adults with heart failure with a preserved ejection fraction with epoetin alfa: single-blind randomized clinical trial of safety and efficacy. Circ Heart Fail. 2013;6:254–63.PubMedCentralPubMedCrossRefGoogle Scholar
  48. 48.
    Haykowsky MJ, Brubaker PH, Morgan TM, Kritchevsky S, Eggebeen J, Kitzman DW. Impaired aerobic capacity and physical functional performance in older heart failure patients with preserved ejection fraction: role of lean body mass. J Gerontol Series A Biol Sci Med Sci. 2013;68:968–75.CrossRefGoogle Scholar
  49. 49.
    Bhella PS, Prasad A, Heinicke K, Hastings JL, Arbab-Zadeh A, Adams-Huet B, Pacini EL, Shibata S, Palmer MD, Newcomer BR, Levine BD. Abnormal haemodynamic response to exercise in heart failure with preserved ejection fraction. Eur J Heart Fail. 2011;13:1296–304.PubMedCentralPubMedCrossRefGoogle Scholar
  50. 50.
    Hummel SL, Kitzman DW. Update on heart failure with preserved ejection fraction. Curr Cardiovasc Risk Rep. 2013;7:495–502.PubMedCrossRefGoogle Scholar
  51. 51.
    Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J. 2011;32:670–9.PubMedCentralPubMedCrossRefGoogle Scholar
  52. 52.
    Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887–98.PubMedCrossRefGoogle Scholar
  53. 53.
    Solomon SD, Janardhanan R, Verma A, Bourgoun M, Daley WL, Purkayastha D, Lacourcière Y, Hippler SE, Fields H, Naqvi TZ, Mulvagh SL, Arnold JMO, Thomas JD, Zile MR, Aurigemma GP. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet. 2007;369:2079–87.PubMedCrossRefGoogle Scholar
  54. 54.
    Edelmann F, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the ALDO-DHF randomized controlled trial. JAMA. 2013;309:781–91.PubMedCrossRefGoogle Scholar
  55. 55.
    Lam CSP, Shah AM, Borlaug BA, Cheng S, Verma A, Izzo J, Oparil S, Aurigemma GP, Thomas JD, Pitt B, Zile MR, Solomon SD. Effect of antihypertensive therapy on ventricular–arterial mechanics, coupling, and efficiency. Eur Heart J. 2013;34:676–83.PubMedCrossRefGoogle Scholar
  56. 56.
    Yancy CW, Jessup M, Bozkurt B, Masoudi FA, Butler J, McBride PE, Casey DE, McMurray JJV, Drazner MH, Mitchell JE, Fonarow GC, Peterson PN, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Riegel B, Sam F, Stevenson LW, Tang WHW, Tsai EJ, Wilkoff BL. ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2013;2013.Google Scholar
  57. 57.
    Lindenfeld J, Albert N, Boehmer J, Collins S, Ezekowitz J, Givertz M, Katz S, Klapholz M, Moser D, Rogers J, Starling R, Stevenson W, Tang WHW, Teerlink J, Walsh M. HFSA 2010 comprehensive heart failure practice guideline. J Card Fail. 2010;16:e1–194.PubMedCrossRefGoogle Scholar
  58. 58.
    Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet. 2003;362:777–81.Google Scholar
  59. 59.
    Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J, PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27:2338–45.Google Scholar
  60. 60.
    Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456–67.PubMedCrossRefGoogle Scholar
  61. 61.
    Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O’Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM; TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383–92.Google Scholar
  62. 62.
    Katz DH, Beussink L, Sauer AJ, Freed BH, Burke MA, Shah SJ. Prevalence, clinical characteristics, and outcomes associated with eccentric versus concentric left ventricular hypertrophy in heart failure with preserved ejection fraction. Am J Cardiol. 2013;112:1158–64.PubMedCrossRefGoogle Scholar
  63. 63.
    Lund LH, Benson L, Dahlström U, Edner M. Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction. JAMA. 2012;308:2108–17.PubMedCrossRefGoogle Scholar
  64. 64.
    Patel K, Fonarow GC, Kitzman DW, Aban IB, Love TE, Allman RM, Gheorghiade M, Ahmed A. Aldosterone antagonists and outcomes in real-world older patients with heart failure and preserved ejection fraction. JACC Heart Fail. 2013;1:40–7.PubMedCentralPubMedCrossRefGoogle Scholar
  65. 65.
    Redfield MM, Chen HH. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013;309:1268–77.PubMedCrossRefGoogle Scholar
  66. 66.
    Reil J-C, Tardif J-C, Ford I, Lloyd SM, O’Meara E, Komajda M, Borer JS, Tavazzi L, Swedberg K, Bohm M. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. J Am Coll Cardiol. 2013;62(21):1977–85.PubMedCrossRefGoogle Scholar
  67. 67.
    Edelmann F, Gelbrich G, Düngen H-D, Fröhling S, Wachter R, Stahrenberg R, Binder L, Töpper A, Lashki DJ, Schwarz S, Herrmann-Lingen C, Löffler M, Hasenfuss G, Halle M, Pieske B. Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the EX-DHF (exercise training in diastolic heart failure) pilot study. J Am Coll Cardiol. 2011;58:1780–91.PubMedCrossRefGoogle Scholar
  68. 68.
    Kitzman D, Brubaker P, Morgan T, Stewart K, Little W. Exercise training in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial. Circ Heart Fail. 2010;3:659–67.PubMedCentralPubMedCrossRefGoogle Scholar
  69. 69.
    Klotz S, Hay I, Zhang G, Maurer M, Wang J, Burkhoff D. Development of heart failure in chronic hypertensive Dahl rats: focus on heart failure with preserved ejection fraction. Hypertension. 2006;47:901–11.PubMedCrossRefGoogle Scholar
  70. 70.
    Ahn J, Varagic J, Slama M, Susic D, Frohlich ED. Cardiac structural and functional responses to salt loading in SHR. Am J Physiol Heart Circ Physiol. 2004;287:H767–72.PubMedCrossRefGoogle Scholar
  71. 71.
    Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62:263–71.PubMedCrossRefGoogle Scholar
  72. 72.
    Hummel SL, Seymour EM, Brook RD, Sheth SS, Ghosh E, Zhu S, Weder AB, Kovacs SJ, Kolias TJ. Low-sodium DASH diet improves diastolic function and ventricular-arterial coupling in hypertensive heart failure with preserved ejection fraction. Circ Heart Fail. 2013;6:1165–71.PubMedCrossRefGoogle Scholar
  73. 73.
    Hummel SL, Seymour EM, Brook RD, Kolias TJ, Sheth SS, Rosenblum HR, Wells JM, Weder AB. Low-sodium dietary approaches to stop hypertension diet reduces blood pressure, arterial stiffness, and oxidative stress in hypertensive heart failure with preserved ejection fraction/novelty and significance. Hypertension. 2012;60:1200–6.PubMedCentralPubMedCrossRefGoogle Scholar
  74. 74.
    Kalogeropoulos A, Georgiopoulou V, Psaty BM, Rodondi N, Smith AL, Harrison DG, Liu Y, Hoffmann U, Bauer DC, Newman AB, Kritchevsky SB, Harris TB, Butler J. Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging, and Body Composition) study. J Am Coll Cardiol. 2010;55:2129–37.PubMedCentralPubMedCrossRefGoogle Scholar
  75. 75.
    Suzuki T, Katz R, Jenny NS, Zakai NA, LeWinter MM, Barzilay JI, Cushman M. Metabolic syndrome, inflammation, and incident heart failure in the elderly: the Cardiovascular Health Study. Circ Heart Fail. 2008;1:242–8.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2014

Authors and Affiliations

  1. 1.Division of Cardiovascular Medicine, Department of Internal MedicineUniversity of MichiganAnn ArborUSA

Personalised recommendations